Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Trial Profile

Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs CD154 gene therapy (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 28 Sep 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Mar 2022.
    • 28 Sep 2017 Planned initiation date changed from 1 Dec 2016 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top